Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-09-05
2008-08-19
Balasubram, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S360000
Reexamination Certificate
active
07414057
ABSTRACT:
Certain novel piperazine urea derivatives are agonists of the human melanocortin-4 receptor (MC-4R) and, in particular, are receptor-subtype selective agonists of MC-4R. They are useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity and diabetes.
REFERENCES:
patent: 5576290 (1996-11-01), Hadley
patent: 5721250 (1998-02-01), Morriello et al.
patent: 5936089 (1999-08-01), Carpino et al.
patent: 6051555 (2000-04-01), Hadley
patent: 6166037 (2000-12-01), Budhu et al.
patent: 6294534 (2001-09-01), Nargund et al.
patent: 6344449 (2002-02-01), Rudolf et al.
patent: 6350760 (2002-02-01), Bakshi et al.
patent: 6458790 (2002-10-01), Palucki et al.
patent: 197 13 000 (1998-10-01), None
patent: WO 96/35713 (1996-11-01), None
patent: WO 96/38471 (1996-12-01), None
patent: WO 99/09984 (1999-03-01), None
patent: WO 99/64002 (1999-12-01), None
patent: WO 00/74649 (2000-12-01), None
patent: WO 01/58891 (2001-08-01), None
patent: WO 01/70337 (2001-09-01), None
patent: WO 01/70708 (2001-09-01), None
patent: WO 01/91752 (2001-12-01), None
patent: WO 02/15909 (2002-02-01), None
patent: WO 02/059095 (2002-08-01), None
patent: WO 02/059107 (2002-08-01), None
patent: WO 02/059108 (2002-08-01), None
patent: WO 02/059117 (2002-08-01), None
patent: WO 02/068387 (2002-09-01), None
patent: WO 02/068388 (2002-09-01), None
patent: WO 02/070511 (2002-09-01), None
patent: WO 03/007949 (2003-01-01), None
patent: WO 03/009847 (2003-02-01), None
patent: WO 03/031410 (2003-04-01), None
Cody et al., Hum. Genet., 105:426-427, 1999.
Schioth et al., Regulatory Peptides, 106, 7-12, 2002.
Rudolf et al., CA 128:197358, 1998.
Wessells et al., J. of Urology, vol. 160(2), (1998), pp. 389-393, “Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction . . . ”.
Giraudo et al., Brain Research, vol. 809 (1998), pp. 302-306, “Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands”.
Chen et al., Cell, vol. 91 (1997), pp. 789-798, “Exocrine gland dysfunction in MC5-R-deficient mice: . . . ”.
Chaki et al., Exp. Opin. Ther. Patents (2001), vol. 11(11), pp. 1677-1692, “Recent advances in feeding suppressing agents: Potential therapeutic strategy for the treatment of obesity”.
Dorr et al., Life Sciences, vol. 58 (1996), pp. 1777-1784, “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study”.
Kask et al., Biochem. & Biophys. Res. Comm., vol. 245 (1998), pp. 90-93, “Selective antagonist for the melanocortin 4 receptor (HS014) increases food intake in free-feeding rats”.
Huszar et al., Cell, vol. 88 (1997), pp. 131-141, “Targeted disruption of the melanocortin-4 receptor results in obesity in mice”.
Wikberg et al., Pharma., vol. 42 (2000), pp. 393-420, “New aspects on the melanocortins and their receptors”.
Wikberg et al., Exp. Op. Ther. Patents, vol 11 (2001), pp. 61-76, “Melanocortin receptors: New opportunities in drug discovery”.
Anderssson, Exp. Op. Ther. Patents, vol. 11 (2001), pp. 1583-1592, “Ligands to the melanocortin receptors”.
Peptides: Frontiers of Peptide Science, Fifteenth American Peptide Symposium, Jun. 14-19, 1997 (Nashville, TN).
Corcos et al., Society for Neuroscience, vol. 23 (1997), Abstract 267.9, “HP 228 is a potent agonist of melanocortin receptor 4, and significantly attenuates obesity and diabetes in Zucker fatty rats”.
Marsh, Nat. Genet., vol. 21 (1999), pp. 119-122, “Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides”.
Bakshi Raman Kumar
Nargund Ravi P.
Palucki Brenda L.
Park Min K.
Ye Zhixiong
Balasubram Venkataraman
Billups Richard C.
Brown Baerbel R.
Fitch Catherine D.
Merck & Co. , Inc.
LandOfFree
Piperazine urea derivatives as melanocortin-4 receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazine urea derivatives as melanocortin-4 receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazine urea derivatives as melanocortin-4 receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4013959